Deutsch English Français

Contact

EP2049143

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2049143

EP2049143 - IMPROVED ANTIBACTERIAL ANTISENSE OLIGONUCLEOTIDE AND METHOD [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 10.01.2014 Database last updated on 24.08.2024
Most recent event Tooltip	10.01.2014	Application deemed to be withdrawn	published on 12.02.2014 [2014/07]
Applicant(s)	For all designated states AVI BioPharma, Inc. Suite 200, 4575 S.W. Research Way Corvallis, OR 97333 / US
	[2009/17]
Inventor(s)	01 / WELLER, Dwight, D. 3323 N.W. Elmwood Drive Corvallis, OR 97330 / US
	02 / GELLER, Bruce, L. 6994 N.W. Concord Drive Corvallis, OR 97330 / US
	03 / IVERSEN, Patrick, L. 5902 N.W. Fair Oaks Place Corvallis, OR 97333 / US
	04 / TILLEY, Lucas, D. 36 Little Eagle Boy Burlington, VT 05408 / US
	05 / HASSINGER, Jed, N. 24319 Price Creek Road Philomath, OR 97370 / US
	[2009/23]
Former [2009/17]	01 / WELLER, Dwight, D. 3323 N.W. Elmwood Drive Corvallis, OR 97330 / US
	02 / GELLER, Bruce, L. 6994 N.W. Concord Drive Corvallis, OR 97330 / US
	03 / IVERSEN, Patrick, L. 5902 N.W. Fair Oaks Place Corvallis, OR 97333 / US
	04 / TILLEY, Lucas, D. 36 Little Eagle Bay Burlingame, VT 05408 / US
	05 / HASSINGER, Jed, N. 24319 Price Creek Road Philomath, OR 97370 / US
Representative(s)	Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB Ganghoferstraße 68 B 80339 München / DE
	[N/P]
Former [2011/42]	Schiweck, Weinzierl & Koch European Patent Attorneys Landsberger Straße 98 80339 München / DE
Former [2009/17]	Barth, Renate, et al Vossius & Partner Siebertstrasse 4 81675 München / DE
Application number, filing date	07794801.6	11.05.2007
	[2009/17]
	WO2007US11431
Priority number, date	US20060487009	13.07.2006 Original published format: US 487009
	[2009/17]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2008008113
	Date:	17.01.2008
	Language:	EN
	[2008/03]
	Type:	A1 Application with search report
	No.:	EP2049143
	Date:	22.04.2009
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 17.01.2008 takes the place of the publication of the European patent application.
	[2009/17]
Search report(s)	International search report - published on:	US	17.01.2008
	(Supplementary) European search report - dispatched on:	EP	18.10.2010
Classification	IPC:	C12N15/11, A61K38/16, A61K31/70, A61K31/675	[2010/46]
	CPC:	A61K48/00 (EP,US); A61P31/04 (EP); C12N15/111 (EP,US); C12N15/113 (EP,US); C12N2310/11 (EP,US); C12N2310/3233 (EP,US); (+) C12N2310/3513 (EP,US); C12N2320/50 (EP,US) (-)
	Former IPC [2009/17]	A61K38/16, A61K31/70, A61K31/675
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR [2009/17]
Title	German:	VERBESSERTES ANTIBAKTERIELLES ANTISENSE-OLIGONUKLEOTID UND VERFAHREN	[2009/17]
	English:	IMPROVED ANTIBACTERIAL ANTISENSE OLIGONUCLEOTIDE AND METHOD	[2009/17]
	French:	OLIGONUCLÉOTIDE ANTISENS ANTIBACTÉRIEN AMÉLIORÉ ET PROCÉDÉ	[2009/17]
Entry into regional phase	13.02.2009	National basic fee paid
	13.02.2009	Search fee paid
	13.02.2009	Designation fee(s) paid
	13.02.2009	Examination fee paid
Examination procedure	13.02.2009	Examination requested [2009/17]
	13.05.2011	Amendment by applicant (claims and/or description)
	21.06.2011	Despatch of a communication from the examining division (Time limit: M06)
	02.01.2012	Reply to a communication from the examining division
	13.03.2012	Despatch of a communication from the examining division (Time limit: M06)
	21.09.2012	Reply to a communication from the examining division
	12.02.2013	Despatch of a communication from the examining division (Time limit: M06)
	23.08.2013	Application deemed to be withdrawn, date of legal effect [2014/07]
	24.09.2013	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2014/07]
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 21.06.2011
Fees paid	Renewal fee
	13.02.2009	Renewal fee patent year 03
	25.05.2010	Renewal fee patent year 04
	25.05.2011	Renewal fee patent year 05
	25.05.2012	Renewal fee patent year 06
	28.05.2013	Renewal fee patent year 07
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[A]WO2004097017 (AVI BIOPHARMA INC [US], et al) [A] 1-15 * the whole document *;
		[A]WO2006050414 (AVI BIOPHARMA INC [US], et al) [A] 1-15 * example 3 *;
		[XP]WO2007009094 (AVI BIOPHARMA INC [US], et al) [XP] 1-15 * the whole document *;
		[A] - GELLER B L ET AL, "Inhibition of gene expression in Escherichia coli by antisense phosphorodiamidate morpholino oligomers", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US LNKD- DOI:10.1128/AAC.47.10.3233-3239.2003, (20031001), vol. 47, no. 10, ISSN 0066-4804, pages 3233 - 3239, XP002402831 [A] 1-15 * table 2 * DOI: http://dx.doi.org/10.1128/AAC.47.10.3233-3239.2003
		[A] - DEERE JESSE ET AL, "Antisense phosphorodiamidate morpholino oligomer length and target position effects on gene-specific inhibition in Escherichia coli", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US LNKD- DOI:10.1128/AAC.49.1.249-255.2005, (20050101), vol. 49, no. 1, ISSN 0066-4804, pages 249 - 255, XP002402833 [A] 1-15 * table 1 * DOI: http://dx.doi.org/10.1128/AAC.49.1.249-255.2005
		[A] - GELLER B L ET AL, "Antisense Phosphorodiamidate Morpholino Oligomer Inhibits Viability of Escherichia coli in Pure Culture and in Mouse Peritonitis", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, OXFORD UNIVERSITY PRESS, GB LNKD- DOI:10.1093/JAC/DKI129, (20050504), vol. 55, ISSN 0305-7453, pages 983 - 988, XP003008448 [A] 1-15 * page 984, column l; figure 1 * DOI: http://dx.doi.org/10.1093/jac/dki129
		[A] - NELSON MICHELLE H ET AL, "Arginine-rich peptide conjugation to morpholino oligomers: effects on antisense activity and specificity", BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US LNKD- DOI:10.1021/BC0501045, (20050701), vol. 16, no. 4, ISSN 1043-1802, pages 959 - 966, XP002543913 [A] 1-15 * table 1 * DOI: http://dx.doi.org/10.1021/bc0501045
		[A] - MOULTON H M ET AL, "CELLULAR UPTAKE OF ANTISENSE MORPHOLINO OLIGOMERS CONJUGATED TO ARGININE-RICH PEPTIDES", BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US LNKD- DOI:10.1021/BC034221G, (20040101), vol. 15, no. 2, ISSN 1043-1802, pages 290 - 299, XP002999956 [A] 1-15 * page 291, column l; table 1 * DOI: http://dx.doi.org/10.1021/bc034221g
		[XP] - TILLEY L D ET AL, "Gene-Specific Effects of Antisense Phosphorodiamidate Morpholino Oligomer-peptide Conjugates on Eschericia coli and Salmonella enterica Serovar Typhimurium in Pure Culture and in Tissue Culture", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US LNKD- DOI:10.1128/AAC.01286-05, (20060801), vol. 50, no. 8, ISSN 0066-4804, pages 2789 - 2796, XP003008447 [XP] 1-15 * figures 4-6 * DOI: http://dx.doi.org/10.1128/AAC.01286-05
	International search	[X]US2006148747 (STEIN DAVID A [US], et al);
		[Y]US7049431 (IVERSEN PATRICK L [US]);
		[A]US6548651 (NIELSEN PETER E [DK], et al)
	Examination	- Derek S. Youngblood ET AL, "Stability of Cell-Penetrating Peptide-Morpholino Oligomer Conjugates in Human Serum and in Cells", Bioconjugate Chemistry, (20070101), vol. 18, no. 1, doi:10.1021/bc060138s, ISSN 1043-1802, pages 50 - 60, XP055031622 DOI: http://dx.doi.org/10.1021/bc060138s

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p